Literature DB >> 21510823

The mechanistic basis for the induction of hepatic steatosis by xenobiotics.

David E Amacher1.   

Abstract

INTRODUCTION: Hepatic steatosis is the histological observation of numerous lipid inclusions due to an excess accumulation of triacylglycerols. They are a concern with new therapeutic candidates because they signify altered lipid metabolism that can progress to more serious liver toxicity. AREAS COVERED: This article is based on an article search using the PubMed database from 1987 to 2011 and confirms associations for several previously marketed drugs with four basic hepatocellular mechanisms. The article also describes how these mechanisms are controlled by master regulators of lipid metabolism, which include gene transcription factors, nuclear receptors, hormonal signaling, energy sensing proteins, endoplasmic reticulum stress signaling and certain key metabolic intermediates. EXPERT OPINION: Drug-induced hepatic steatosis is typically not detectable by conventional means other than invasive histological examinations. By understanding the basic mechanisms, key regulators and energy signaling systems of the liver, the investigator is better equipped to avoid xenobiotics with steatogenic potential in the drug discovery or early development process. There are now a number of methods for detecting this potential, specifically gene expression or metabolomic profiling and pathway analysis or mechanism-based in vitro systems.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21510823     DOI: 10.1517/17425255.2011.577740

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  9 in total

Review 1.  Drug-induced steatohepatitis.

Authors:  Ajit Dash; Robert A Figler; Arun J Sanyal; Brian R Wamhoff
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-27       Impact factor: 4.481

2.  Identification of the Potential Molecular Mechanisms Linking RUNX1 Activity with Nonalcoholic Fatty Liver Disease, by Means of Systems Biology.

Authors:  Laia Bertran; Ailende Eigbefoh-Addeh; Marta Portillo-Carrasquer; Andrea Barrientos-Riosalido; Jessica Binetti; Carmen Aguilar; Javier Ugarte Chicote; Helena Bartra; Laura Artigas; Mireia Coma; Cristóbal Richart; Teresa Auguet
Journal:  Biomedicines       Date:  2022-06-03

3.  Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis.

Authors:  John D Clarke; Tatiana Sharapova; April D Lake; Eric Blomme; Jonathan Maher; Nathan J Cherrington
Journal:  J Appl Toxicol       Date:  2013-11-12       Impact factor: 3.446

Review 4.  Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.

Authors:  Mathieu Vinken
Journal:  Chem Res Toxicol       Date:  2015-07-02       Impact factor: 3.739

5.  Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices.

Authors:  Ewa Szalowska; Bart van der Burg; Hai-Yen Man; Peter J M Hendriksen; Ad A C M Peijnenburg
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

6.  Identification of novel clinical factors associated with hepatic fat accumulation in extreme obesity.

Authors:  Glenn S Gerhard; Peter Benotti; G Craig Wood; Xin Chu; George Argyropoulos; Anthony Petrick; William E Strodel; Jon D Gabrielsen; Anna Ibele; Christopher D Still; Christopher Kingsley; Johanna DiStefano
Journal:  J Obes       Date:  2014-12-24

Review 7.  Flame Retardants-Mediated Interferon Signaling in the Pathogenesis of Nonalcoholic Fatty Liver Disease.

Authors:  Chander K Negi; Sabbir Khan; Hubert Dirven; Lola Bajard; Luděk Bláha
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

8.  Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.

Authors:  Mathieu Vinken
Journal:  Methods Mol Biol       Date:  2016

9.  Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades.

Authors:  Zhichao Liu; Yuping Wang; Jürgen Borlak; Weida Tong
Journal:  Sci Rep       Date:  2016-04-05       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.